Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Repinotan HCl (BAYX3702)
Repinotan · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Arm 1 | ACTIVE_COMPARATOR | - |
| Arm 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Repinotan HCl (BAYX3702) | DRUG | All patients receive 1.25 mg of repinotan |
| Placebo | DRUG | All patients receive 1.25 mg of placebo |
Inclusion Criteria: * Acute ischemic stroke of hemispheric localization (exclude brainstem and cerebellum), of suspected thromboembolic origin. * Males or females aged 18 years or over. * National Institute of Health Stroke Scale (NIH-SS) total score 8 to 23 with a motor deficit \>/= 2 (for either ...
Top 5 of 19 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Johnson & Johnson | JNJ | 1 | PHASE3 | Milvexian |
| Grace Therapeutics, Inc. | GRCE | 1 | PHASE3 | GTX-104 |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | TAK-755 |
| CervoMed Inc. | CRVO | 1 | PHASE2 | Neflamapimod |
| DiaMedica Therapeutics Inc. | DMAC | 1 | PHASE2 | DM199 |
Repinotan was studied as a treatment for acute ischemic stroke. It was evaluated in a Phase 2 clinical trial in patients with acute ischemic stroke, a condition in which blood flow to part of the brain is blocked. Repinotan is an investigational small molecule and is not an approved therapy.
Repinotan targets HTR1A, the serotonin 1A receptor, and acts as an agonist at that receptor. By binding and activating HTR1A, the small molecule is designed to influence serotonergic signaling. This receptor target is the basis for its investigation in acute ischemic stroke.
Repinotan was developed by Bayer AG, which trades on the OTC market under the ticker BAYRY. Bayer sponsored the clinical program evaluating the compound in acute ischemic stroke. Repinotan HCl is also known by the code BAYX3702.
Repinotan is in Phase 2 development. It is an investigational small molecule and has not been approved by the FDA for any indication. The Phase 2 program in acute ischemic stroke has been completed, and no trials are currently active.
Repinotan was studied in one clinical trial, NCT00044915, titled Repinotan in Patients With Acute Ischemic Stroke. This completed Phase 2 trial enrolled 782 patients, was randomized, double blind, and placebo controlled, and ran across the United States, Australia, Austria, Belgium, Canada, Finland, France, Germany, Hungary, Israel, Italy, Netherlands, Spain, Sweden, and the United Kingdom.
Yes. Repinotan HCl, also referenced by the code BAYX3702, is the same compound as Repinotan. The hydrochloride salt form and the internal Bayer code refer to the identical small molecule HTR1A agonist that was studied in acute ischemic stroke.